#OncFive
LightNews LightNews
onclive.bsky.social
Last week's #OncFive:

✅ Pirtobrutinib OK'd in 1L CLL/SLL #lymsm #leusm
🎗️ Priority review: elinzanetant for breast cancer #bcsm
🩸 Tabelecleucel BLA resubmitted in EBV+ PTLD
🫁 Savolitinib+osimertinib NDA in MET+ NSCLC #lcsm
🫁 Zipalertinib NDA starts in NSCLC

🔗: www.onclive.com/view/the-onc...
The OncFive: Top Oncology Articles for the Week of 9/27/2026 | OncLive
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
www.onclive.com
October 5, 2026 at 3:44 PM
onclive.bsky.social
🌟 It's time for the #OncFive 5️⃣ 🌟 Learn more about the top 5 #oncology stories from this week: onclive.com/view/the-onc... #bcsm #mmsm
September 28, 2025 at 4:20 PM
onclive.bsky.social
#ICYMI: We present the #OncFive 5️⃣: the top 5 #oncology articles of the past week. Learn more about the items on the list 🔗🔎: www.onclive.com/view/the-onc...
March 3, 2025 at 9:38 PM
onclive.bsky.social
It's time for this week's #OncFive 5️⃣, your quick roundup of the 5 top stories from the world of #oncology. Learn more about what made the list 🔗: www.onclive.com/view/the-onc...
April 12, 2025 at 4:57 PM
onclive.bsky.social
This week’s #OncFive 5⃣:

✅ @fda.gov clears T-DXd combo in HER2+ breast cancer
💉 SC amivantamab approved for EGFR+ NSCLC
🧬 Rucaparib cleared in BRCA+ mCRPC
🏆 Priority voucher for teclistamab combo in myeloma
🚻 Periop EV combo meets EFS/OS in MIBC

🔗: www.onclive.com/view/the-onc...
December 21, 2025 at 12:40 AM
onclive.bsky.social
🌟 Last week's #OncFive 🌟:
🎗️ @fda.gov approved camizestrant+CDK4/6 inihibition for ESR1-mutated breast cancer
🩸 Ropeginterferon alfa-2b approved for ET
🫁 Daraxonrasib produced durable ORR in RAS-mutated NSCLC
➕ Many more!

Learn more 🔗: www.onclive.com/view/the-onc...
September 8, 2026 at 1:40 PM
onclive.bsky.social
🌟 This week's #OncFive 🌟:

🎗️ FDA clears gedatolisib in select PIK3CA WT mBC
🧬 Selpercatinib full approval in RET fusion+ tumors
🚫 3rd CRL for rivoceranib/camrelizumab in 1L HCC
🩸 NDA accepted for mezigdomide combo in r/r myeloma
🟡 Fast track for SOT109 in CRC

🔗: www.onclive.com/view/the-onc...
The OncFive: Top Oncology Articles for the Week of 7/12 | OncLive
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
www.onclive.com
July 18, 2026 at 7:24 PM
longtail-news.bsky.social
Feed: "MashupMD"
By: Mashup MD on Saturday, August 30, 2025
The OncFive: Top Oncology Articles for the Week of 8/24
Up-to-date medical news aggregated from trusted medical associations, journals, physicians and news outlets from around the world.
www.mashupmd.com
August 30, 2025 at 12:43 PM
longtail-news.bsky.social
Feed: "MashupMD"
By: Mashup MD on Sunday, May 11, 2025
The OncFive: Top Oncology Articles for the Week of 4/27
Up-to-date medical news aggregated from trusted medical associations, journals, physicians and news outlets from around the world.
www.mashupmd.com
May 11, 2025 at 6:12 AM
onclive.bsky.social
🌟 This week's #OncFive 🌟:
🎗️ @fda.gov approves Dato-DXd in PD-L1–ineligible TNBC
🫁 Priority review for sevabertinib in 1L HER2-mutant NSCLC
🔵 sBLA accepted for nogapendekin/BCG in papillary NMIBC
🧬 FTD for suplexa in MSI-H CRC
🩸 ODD for CLN-049 in r/r AML

🔗: www.onclive.com/view/the-onc...
The OncFive: Top Oncology Articles for the Week of 5/17 | OncLive
The FDA approved Dato-DXd for PD-1/PD-L1–ineligible triple-negative breast cancer, granted priority review to sevabertinib in HER2-mutant NSCLC, and more.
www.onclive.com
May 23, 2026 at 7:52 PM
onclive.bsky.social
🌟 This week's #OncFive 🌟:

🎗️ FDA clears T-DXd in early HER2+ breast cancer
🔵 Adjuvant atezolizumab approved for MRD+ MIBC
🚫 Tazemetostat withdrawn over SPM risk
🩸 Sonrotoclax approval in R/RMCL
🩸 Oral dec/ced + venetoclax approved in newly dx AML

🔗: www.onclive.com/view/the-onc...
The OncFive: Top Oncology Articles for the Week of 5/10 | OncLive
The FDA approved T-DXd in early HER2+ breast cancer, adjuvant atezolizumab in MRD+ MIBC, and more.
www.onclive.com
May 17, 2026 at 2:42 AM
onclive.bsky.social
This week’s #OncFive 5⃣:

✅ @fda.gov clears vepdegestrant in ESR1+ breast cancer
🧪 ODAC votes against camizestrant in breast cancer
🧬 ODAC backs capivasertib combo in mHSPC
🚀 Expanded access for daraxonrasib in PDAC
🔎 Priority review to zanidatamab combos in HER2+ GEA

www.onclive.com/view/the-onc...
The OncFive: Top Oncology Articles for the Week of 4/26 | OncLive
The FDA cleared vepdegestrant in ER+ breast cancer with ESR1 mutations, ODAC voted on key questions in breast and prostate cancer, and more.
www.onclive.com
May 2, 2026 at 6:53 PM
onclive.bsky.social
🌟 This week’s #OncFive 5⃣:

🚀 Priority review for periop EV + pembro in MIBC
💉 @fda.gov review extended for SC isatuximab in myeloma
📉 Pembro combos miss mark in frontline ccRCC
🧪 Daraxonrasib shows promise in PDAC
🌍 EC clears tovorafenib for pLGG

Learn more 🔗: www.onclive.com/view/the-onc...
The OncFive: Top Oncology Articles for the Week of 4/19 | OncLive
The FDA grants priority review to enfortumab vedotin-ejfv sBLAs in MIBC, the review period for subcutaneous isatuximab BLA in myeloma has been extended, and more.
www.onclive.com
April 25, 2026 at 11:57 PM
onclive.bsky.social
🧬 It's time for the #OncFive, which rounds up the top 5️⃣ #oncology news of the week. Read more about what made the list 🔗 www.onclive.com/view/the-onc...
March 21, 2026 at 1:56 PM
onclive.bsky.social
This week’s #OncFive 5⃣:
✅ @fda.gov approval for niraparib/abiraterone in BRCA2+ mCSPC
🔎Priority review for nivolumab+AVD in HL
📈Durable toripalimab OS in NPC
🛑Phase 3 GI setback
🟢Orphan drug status granted to a novel ADC for SCLC

Learn more 🔗: www.onclive.com/view/the-onc...
December 13, 2025 at 4:19 PM
onclive.bsky.social
It's time for the #OncFive 5⃣, where we bring you the top 5 stories of the week in the world of #oncology.

Learn more about the items on the list: www.onclive.com/view/the-onc...
October 11, 2025 at 7:45 PM
onclive.bsky.social
🌟 It's time for the #OncFive 🌟 : your go-to source for the top 5️⃣ #oncology articles of the week! 🌟

📖 Read more about the items that made the list: www.onclive.com/view/the-onc...

#pcsm #bcsm #lcsm #WCLC25 #oncology
August 31, 2025 at 1:26 AM
onclive.bsky.social
Stay ahead of the curve with the #OncFive 5️⃣—a fast, focused roundup of the week’s top #oncology developments in drug approvals, trial results, and expert insights.

Learn more about the items that made the list 🔗: onclive.com/view/the-onc...
July 27, 2025 at 2:00 AM
onclive.bsky.social
It's time for the #OncFive 5️⃣, the top #oncology articles of the week. Read more about the items that made the list 🔗: www.onclive.com/view/the-onc...
July 5, 2025 at 7:45 PM
onclive.bsky.social
🚨 It's time for the #OncFive 5️⃣🚨

Learn more about the top #oncology stories of the past week 🔗: www.onclive.com/view/the-onc...
June 28, 2025 at 4:54 PM
onclive.bsky.social
It's Saturday, which means it's time for the #OncFive 5️⃣. Here are the top 5 #oncology articles of the week 🔗: www.onclive.com/view/the-onc...
June 21, 2025 at 9:20 PM
onclive.bsky.social
It's the #OncFive 5️⃣: Your quick roundup of the 5 top stories from the world of #oncology.

Learn more about the items that made the list 🔗: www.onclive.com/view/the-onc...
June 15, 2025 at 2:25 PM
onclive.bsky.social
It's time for the #OncFive 5️⃣, the top 5 #oncology stories of the week! Read more about what made the list 🔗: www.onclive.com/view/the-onc... #lymsm #pcsm #mmsm #oncology
May 24, 2025 at 5:34 PM
onclive.bsky.social
Stay up to date on the latest news in #oncology by checking out this week’s #OncFive 5️⃣. Learn more about what made the list 🔗: onclive.com/view/the-onc... #bcsm #lcsm #AUA25
April 27, 2025 at 3:41 AM